Procore signs multi-year strategic collaboration agreement with AWS
XTL Biopharmaceuticals Ltd., a micro-cap biotechnology company with a market capitalization of $12.58 million, has amended the record date for its upcoming Annual and Extraordinary General Meeting of Shareholders. According to an SEC filing submitted today, the company has changed the record date from June 19, 2025, to June 18, 2025, as June 19 is a Federal Holiday.
The meeting will be held on July 21, 2025, at 4:00 p.m. Israel time at the offices of the company’s attorneys, Doron Tikotzky Kantor Gutman & Amit Gross, located at 7 Metsada St., B.S.R Tower 4, 33 Floor, Bnei Brak, Israel.
The company has furnished an amended notice and proxy statement describing the proposals to be voted upon at the meeting, along with a form of proxy card that allows shareholders to vote without attending in person.
XTL Biopharmaceuticals, which trades under the ticker 001-36000, is headquartered at 26 Ben-Gurion St., Ramat Gan, Israel. The company files annual reports under Form 20-F.
The amendment was signed by CEO Noam Band and submitted to the Securities and Exchange Commission as a Form 6-K/A for the month of June 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.